Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)], Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles -Global Forecast to 2030" has been added to ResearchAndMarkets.com's offering.
The global CRISPR market is set to expand from USD 3.21 billion in 2025 to USD 5.47 billion by 2030, registering a robust CAGR of 11.2%
The report presents an analysis of market drivers, focusing on the rising demand for CRISPR-based therapies and ongoing technological advancements. It identifies key opportunities for CRISPR in areas such as vaccines and genetic disease treatments. A comprehensive evaluation of market shares and growth strategies of leading companies is included, along with an overview of challenges, particularly regulatory hurdles, that affect market progression.
Growth is fueled by the technology's expanding use in research, clinical, and industrial applications, supported by increased investments in biotechnology R&D and the growing prevalence of genetic disorders. As CRISPR tools and delivery systems improve, and regulatory frameworks become more supportive, the integration of CRISPR into research and therapeutic pipelines accelerates.
Leading companies include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, GenScript, Takara Bio, Creative Biogene, Fujian SunyBiotech, Caribou Biosciences, Lonza Group, Danaher Corporation, among others.
Products Dominated the Market in 2024
The CRISPR market is divided into products and services. The products segment, which includes CRISPR kits & enzymes and CRISPR libraries, leads the market. These products are essential in academic, clinical, and industrial research for genome editing and therapeutic development. This segment's growth is driven by the demand for standardized and innovative CRISPR products.
Drug Discovery & Development: A Fast-Growing Application Segment
Within applications, drug discovery & development is the largest and fastest-growing segment, leveraging CRISPR to find gene-disease links and streamline drug functions. This reduces timelines and increases success probabilities. Pharmaceutical and biotechnology firms are pivotal in incorporating CRISPR for personalized medicine and functional genomics, further driving the technology's adoption.
Pharmaceutical & Biotechnology Companies' Market Dominance in 2024
These companies led the CRISPR products market in 2024, thanks to increased investment in cell and gene therapies, and the need for precise genetic tools. Their financial strength allows them to implement advanced CRISPR technologies effectively, bolstering their market position.
North America's Leadership in the CRISPR Market
North America, with its prominent research institutions and substantial biotech investments, captured the largest CRISPR market share in 2024. The region's emphasis on medical research and personalized medicine offers it a competitive edge. European markets, especially in Germany, the UK, and France, are also seeing robust growth due to heightened R&D activity.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 267 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value (USD) in 2025 | $3.21 Billion |
| Forecasted Market Value (USD) by 2030 | $5.47 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Global |
Market Dynamics
Drivers
- Growing Demand for Crispr-Based Gene Therapies
- Advancements in Crispr Technology
- Growing Government and Private Investments and Funding for Crispr Technology
Restraints
- Technical Challenges Associated With Crispr Technology
Opportunities
- Development of New Vaccines and Treatments for Genetic Diseases
- Expanding Industrial and Agricultural Applications of Crispr
Challenges
- Regulatory Hurdles for Crispr Advancements
Technology Analysis
- Key Technologies
- Crispr-Cas Systems
- Grna Design & Optimization
- High-Throughput Crispr Screening
- Complementary Technologies
- Synthetic Biology
- Single-Cell Genomics
- Next-Generation Sequencing
- Adjacent Technologies
- Stem Cell Engineering
- Synthetic Dna & Gene Synthesis
- Microfluidics
Company Profiles
- Thermo Fisher Scientific Inc.
- Merck Kgaa
- Agilent Technologies, Inc.
- Genscript
- Revvity
- Lonza
- Danaher Corporation
- Takara Bio Inc.
- Creative Biogene
- Fujian Sunybiotech Co., Ltd.
- Editco
- Caribou Biosciences, Inc.
- Hera Biolabs
- Origene Technologies, Inc.
- Cellecta, Inc.
- Mammoth Biosciences, Inc.
- Applied Stemcell
- New England Biolabs
- Toolgen, Inc.
- Genecopoeia, Inc.
- Twist Bioscience
- Synthego
- Egenesis
- Inscripta, Inc.
- Precision Biosciences
For more information about this report visit https://www.researchandmarkets.com/r/ue864[product-kits?w=12
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
